Medicine and Dentistry
Testis Cancer
100%
Malignant Neoplasm
60%
Neoplasm
50%
Cisplatin
45%
Breast Cancer
37%
Radiation Therapy
30%
Disease
29%
Germinoma
27%
Cardiovascular Disease
26%
Cardiovascular System
25%
Cancer Therapy
23%
Ovarian Cancer
23%
Biological Marker
21%
Positron Emission Tomography
20%
Cardiovascular Risk
19%
Metabolic Syndrome
19%
Positron Emission Tomography
18%
Germ Cell Cancer
18%
Radioactive Tracer
15%
Overall Survival
14%
Oncology
14%
Programmed Cell Death
13%
Heart Function
12%
Cardiotoxicity
12%
Zirconium 89
12%
Prevalence
11%
Progression Free Survival
11%
Bleomycin
11%
Hazard Ratio
10%
Gastrointestinal Stromal Tumor
10%
Heart Failure
9%
Late Effect
9%
Anthracycline
9%
Cancer
9%
Kidney Function
9%
Childhood Cancer
9%
Surgery
9%
Blood Vessel Injury
8%
Quality of Life
8%
Pharmacokinetics
8%
Combination Chemotherapy
7%
Amino Terminal Sequence
7%
Non Seminomatous Germinoma
7%
Transitional Cell Carcinoma
7%
Gamma Urogastrone
7%
Homologous Recombination
7%
Population
7%
Orchiectomy
7%
Plasminogen Activator Inhibitor-1
7%
Diagnosis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
93%
Testis Cancer
81%
Cisplatin
59%
Malignant Neoplasm
55%
Neoplasm
46%
Breast Cancer
34%
Pharmacokinetics
31%
Disease
27%
Cardiotoxicity
23%
Bleomycin
21%
Anthracycline
19%
Biological Marker
19%
Solid Malignant Neoplasm
18%
Germ Cell Cancer
17%
Ovary Cancer
16%
Overall Survival
16%
Heart Failure
15%
Cardiovascular Risk
15%
Cardiovascular Disease
15%
Trastuzumab
14%
Gastrointestinal Stromal Tumor
13%
Progression Free Survival
12%
Brain Natriuretic Peptide
11%
Carboplatin
11%
Epidermal Growth Factor Receptor 2
10%
Gemcitabine
10%
Tracer
10%
Angiogenesis Inhibitor
10%
Imatinib
9%
Protein P53
9%
Zirconium 89
9%
Paclitaxel
8%
Lung Toxicity
8%
Gamma Urogastrone
8%
Pharmacodynamics
7%
Non Seminomatous Germinoma
7%
Adverse Event
7%
Thrombospondin 1
7%
Bevacizumab
7%
Maximum Tolerated Dose
7%
Prevalence
7%
Lobaplatin
7%
Germ Cell Tumor
7%
Inflammation
7%
Metabolic Syndrome X
7%
Fluorouracil
6%
Anticarcinogen
6%
Etoposide
6%
Diarrhea
6%
Second Cancer
6%
Keyphrases
Testicular Cancer
43%
Chemotherapy
23%
Cancer Treatment
17%
Cancer Patients
16%
Testicular Cancer Survivors
14%
Cisplatin-based Chemotherapy
14%
Phase I Study
13%
Cisplatin
12%
Cardiovascular Risk
11%
Cardiovascular Morbidity
10%
Pharmacokinetics
9%
Germ Cell Tumor
9%
Metabolic Syndrome
8%
Radiotherapy
8%
Cardiovascular Disease
8%
Late Effects
7%
Testicular Germ Cell Tumor
7%
Advanced Ovarian Cancer
7%
Hazard Ratio
7%
In Cancer
6%
Carboplatin
6%
Long-term Breast Cancer Survivors
5%
Cardiovascular Events
5%
Confidence Interval
5%
Thrombospondin-1 (TSP-1)
5%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
5%
Exercise Intervention
5%
Maximum Tolerated Dose
5%
Solid Tumors
5%
Platinum-based Chemotherapy
5%
Non-seminomatous Germ Cell Tumor (NSGCT)
5%
Collaborative Groups
5%
High Risk
5%
Antibody Uptake
5%
5-fluorouracil (5-FU)
5%
Cardiac Function
5%
Zr-89
5%
Cardiac Substructures
5%
Angiogenesis Inhibitors
5%
Long-term Survivors
5%
Vascular Toxicity
5%
Gemcitabine Plus Cisplatin
5%
Metachronous
5%